Bladder cancer gains approval without its own trial

The FDA’s decision tests whether closely related bladder-cancer patterns can share clinical evidence instead of each needing its own efficacy trial. On October 14, 2026, it expanded Anktiva’s use after relying on a 77-person trial in the related CIS form of the disease. In a urology clinic, patients with returning papillary tumors can receive treatment through a catheter before bladder removal, if examinations show the cancer remains controlled.

For people whose high-risk bladder cancer keeps returning after BCG, the usual choice has been grim: continue treatment that may no longer work, or have the bladder removed. Until now, adults with high-grade papillary-only tumors that had not reached the bladder muscle had no FDA-approved treatment specifically for that pattern of disease. Waiting while cancer returns or grows can delay the surgery that may ultimately be needed.

The two forms of cancer behind the decision

BCG is a bacterium placed inside the bladder after doctors remove non-muscle-invasive tumors. It stimulates the immune system and has long been a standard treatment for high-risk disease. But these cancers can return repeatedly. Patients may need regular cystoscopies, tumor removal and more treatment delivered inside the bladder.

Two tumor patterns matter here. Carcinoma in situ, or CIS, is a flat form of high-grade cancer. Papillary tumors grow in finger-like shapes. “BCG-unresponsive” means the cancer is no longer being controlled by BCG. For high-risk cancer in this situation, removing the bladder can be the definitive treatment, but it is life-changing surgery.

Normally, a drug approval depends on evidence from the same patient group named on the label. That can be difficult when a cancer has several closely related forms and each group is small. The FDA’s decision asks whether evidence from one form can support treatment for another when the diseases have sufficiently similar biology and risks.

An approval built from a related trial

On October 14, 2026, the FDA expanded the approved use of Anktiva, given together with BCG, to adults with BCG-unresponsive, high-grade papillary-only bladder cancer that has not spread into the bladder muscle. It is the first FDA-approved treatment specifically for this group. The treatment is delivered directly into the bladder through a catheter.

The important step was not a new efficacy trial in papillary-only disease. The FDA relied on results from Anktiva’s earlier approval for CIS, along with clinical and laboratory evidence that CIS and high-grade papillary-only disease are alike in meaningful ways. That earlier trial enrolled 77 adults, some of whom also had papillary tumors. In it, 62% achieved a complete response, meaning no high-grade cancer was found during follow-up. Among those responders, 58% maintained that response for at least 12 months, and 40% for at least 24 months.

A complete response does not prove that cancer will never return. Treatment is given weekly for six weeks, with more treatment based on the patient’s response, and can continue for up to 37 months. It should stop if cancer remains after a second six-week course, returns, progresses or causes unacceptable side effects.

What changes in a clinic

In a urology clinic, a person whose high-grade papillary tumors return after BCG can now receive a labeled bladder-directed treatment instead of being told that no FDA-approved therapy specifically covers that tumor pattern. If repeat examinations show the cancer is controlled, this could give some patients more time before bladder removal.

The larger consequence may be for drug development. If regulators accept that closely related bladder-cancer patterns share clinically meaningful biology and risk, developers may be able to use evidence across them rather than treating every microscopic category as a separate drug program. That could make small cancer populations more practical to study.

The boundary is important. The prescribing information warns that delaying surgery to remove all or part of the bladder can allow cancer to spread and can be fatal. Surgery remains essential when treatment fails. The FDA is also working to finalize draft guidance on using CIS evidence to support approvals for BCG-unresponsive, high-grade papillary-only disease. The new route will matter only if the diseases truly match closely enough, and if patients continue to be monitored so that a failed treatment does not postpone necessary surgery.

出典

FDA, “FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer”